Last reviewed · How we verify
Clindamycin & Rifampin
Clindamycin & Rifampin is a Small molecule drug developed by Henry Ford Health System. It is currently in Phase 1 development.
Clindamycin is a small molecule that inhibits the bacterial 70S ribosome, classified as an inhibitor. It is used to treat various staphylococcal infections, including prosthetic-joint infections, and is often combined with rifampin in clinical trials.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Clindamycin & Rifampin |
|---|---|
| Sponsor | Henry Ford Health System |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- diarrhea
- respiratory infection
- fever
- Upper respiratory tract infection
- Cerebral hemorrhage
- Subdural hematoma
- Epilepsia
- Pneumonia
Key clinical trials
- Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis (PHASE4)
- Comparison Between Two Durations of Antibiotherapy for Non-surgically-treated Diabetic Foot Osteomyelitis (CHRONOS-2) (PHASE3)
- Studying the Distribution of Accessory Gene Regulator (Agr) Quorum Sensing System and the Prevalence of Linezolid and Mupirocin Resistance in Biofilm Producer/Non Producer Staphylococcus Aureus in Sohag University Hospitals (NA)
- Rifampicin Combination Therapy Versus Monotherapy for Staphylococcal Prosthetic Joint Infection (PHASE4)
- Pharmacokinetics (PK) of Antistaphylococcal Antibiotics in Infants (NICHD-2012-02-Staph Trio) (PHASE1)
- Bactiseal Catheter Safety Registry in China
- Genetic Determinants of Clindamycin/Rifampin Interaction
- Trial Comparing Efficacy of Treatments for Hidradenitis Suppurativa (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clindamycin & Rifampin CI brief — competitive landscape report
- Clindamycin & Rifampin updates RSS · CI watch RSS
- Henry Ford Health System portfolio CI
Frequently asked questions about Clindamycin & Rifampin
What is Clindamycin & Rifampin?
Who makes Clindamycin & Rifampin?
What development phase is Clindamycin & Rifampin in?
What are the side effects of Clindamycin & Rifampin?
Related
- Manufacturer: Henry Ford Health System — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing